Royal Bank of Canada’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-3,615
| Closed | -$137K | – | 7995 |
|
|
2021
Q1 | $137K | Buy |
3,615
+1,370
| +61% | +$34.2K | ﹤0.01% | 5228 |
|
|
2020
Q4 | $38K | Buy |
2,245
+264
| +13% | +$3.31K | ﹤0.01% | 5775 |
|
|
2020
Q3 | $10K | Buy |
1,981
+30
| +2% | +$152 | ﹤0.01% | 5935 |
|
|
2020
Q2 | $12K | Sell |
1,951
-357
| -15% | -$1.47K | ﹤0.01% | 5784 |
|
|
2020
Q1 | $5K | Sell |
2,308
-2,193
| -49% | -$9.31K | ﹤0.01% | 6075 |
|
|
2019
Q4 | $20K | Buy |
4,501
+2,540
| +130% | +$10.1K | ﹤0.01% | 5860 |
|
|
2019
Q3 | $7K | Buy |
1,961
+1,261
| +180% | +$6.92K | ﹤0.01% | 5922 |
|
|
2019
Q2 | $4K | Sell |
700
-250
| -26% | -$2.39K | ﹤0.01% | 6437 |
|
|
2019
Q1 | $13K | Buy |
950
+221
| +30% | +$2.52K | ﹤0.01% | 5874 |
|
|
2018
Q4 | $7K | Sell |
729
-959
| -57% | -$11.4K | ﹤0.01% | 6071 |
|
|
2018
Q3 | $23K | Sell |
1,688
-464
| -22% | -$6.9K | ﹤0.01% | 5610 |
|
|
2018
Q2 | $34K | Buy |
2,152
+282
| +15% | +$4.92K | ﹤0.01% | 5321 |
|
|
2018
Q1 | $32K | Buy |
1,870
+801
| +75% | +$15.6K | ﹤0.01% | 5262 |
|
|
2017
Q4 | $23K | Sell |
1,069
-2,154
| -67% | -$69.3K | ﹤0.01% | 5554 |
|
|
2017
Q3 | $132K | Buy |
3,223
+2,380
| +282% | +$74.7K | ﹤0.01% | 4817 |
|
|
2017
Q2 | $25K | Sell |
843
-7,487
| -90% | -$234K | ﹤0.01% | 5461 |
|
|
2017
Q1 | $302K | Buy |
8,330
+2,357
| +39% | +$104K | ﹤0.01% | 4053 |
|
|
2016
Q4 | $299K | Sell |
5,973
-7,932
| -57% | -$417K | ﹤0.01% | 4206 |
|
|
2016
Q3 | $730K | Buy |
13,905
+12,905
| +1,291% | +$616K | ﹤0.01% | 3396 |
|
|
2016
Q2 | $41K | Buy |
+1,000
| New | +$43.5K | ﹤0.01% | 5203 |
|
|
2015
Q4 | – | Sell |
-964
| Closed | -$15K | – | 6926 |
|
|
2015
Q3 | $15K | Buy |
+964
| New | +$20.7K | ﹤0.01% | 5696 |
|
Royal Bank of Canada's FPRX Position: Q2 2021 in Review
Royal Bank of Canada sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 3,615 shares — an estimated $137K sold.
Royal Bank of Canada first reported a position in FPRX in Q3 2015 and held it in 21 quarters. The position peaked at $730K in Q3 2016. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Royal Bank of Canada reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Royal Bank of Canada sold 3,615 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $137K.
- Royal Bank of Canada first reported a position in Five Prime Therapeutics, Inc. in Q3 2015 and held it in 21 quarters.
- Royal Bank of Canada's Five Prime Therapeutics, Inc. position peaked at $730K in Q3 2016.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Royal Bank of Canada's 13F filing for Q2 2021, filed 16 Aug 2021.